Cancer risk associated with inherited BRCA2 mutations
If you have tested positive for a BRCA2 mutation, we recommend that you consult with a genetics expert who can assess your personal and family history of cancer, and help you determine the best risk management plan.
Research on lifetime cancer risk for people with BRCA2 mutations has varied. The following risks are estimates based on review of different large studies. The average age of a cancer diagnosis is younger in people with a BRCA2 mutation than people who do not have a mutation.
Risks in women
- Breast cancer: The lifetime risk for a women with a BRCA2 mutation is 45 - 55 percent compared to 12.5 percent for an average risk woman.
- Ovarian cancer: The lifetime risk for a women with a BRCA2 mutation is 10 - 20 percent compared with 1.3 percent for an average risk woman.
- Second breast cancer in women who have alread been diagnosed with breast cancer: The lifetime risk is about 26 percent.
Risks in men
- Prostate cancer: The lifetime risk for a man with a BRCA2 mutation is about 32 percent compared to 12 percent for an average risk man. Prostate cancers in men with inherited BRCA2 mutations may be more aggressive than in men without an inherited mutation.
- Breast cancer: The lifetime risk for a man with a BRCA2 mutation is about 7 percent. Breast cancers in men with inherited BRCA2 mutations tend to occur at a younger age than men who do not have an inherited mutation.
Risks in both men and women
- Pancreatic cancer: The lifetime risk for a person with a BRCA2 mutation is about 5 percent compared to 1 percent for an average risk person.
- Research on how mutations in the BRCA2 gene affect cancer risk is ongoing. Some research suggests that BRCA2 mutations may increase risk for melanoma. However, because these studies are not conclusive, genetics experts often look at a person’s family history of cancer to help people with BRCA2 mutations understand their risk for additional cancers.
The following are studies are looking at cancer risks in people with a BRCA2 mutation.
- NCT00579488: Clinical Significance of Germline BRCA Mutations. The goal of this study is to help us learn more about the roles of genes and cancers that run in families.
- Identification and Analysis of Families With Genetic Susceptibility To Cancer Registry. The research laboratory at the Abramson Cancer Center is studying genetic sources of cancer risk. A number of research projects are performed in collaboration with this registry.